The present application includes compositions for treating ectoparasite infestations, including killing ectoparasites and/or their ova, the compositions comprising one or more fatty acid esters and one or more linear polymeric siloxanes. Also included are kits comprising the compositions and methods of treating ectoparasite infestations, including methods of killing ectoparasites and/or their ova, using the compositions.

The present invention relates to a multi-postbiotics-compounded rejuvenating essence, which includes the following components in percentage by weight: 8.0-13.0% of butanediol, 2.0-3.0% of triglyceride octoate/caprate/succinate, 2.0-3.0% of polyglutamate sodium, 0.5-1.0% of extract of Japanese Ardisia herb stems, 0.5-1.0% of yeast/rice ferment filtrate, 0.5-1.0% of fission yeast mycelium ferment filtrate, 0.5-1.0% of lactobacillus/mung bean extract/sodium glutamate ferment filtrate, 0.5-1.0% of lactobacillus ferment, 0.5-1.0% of bacillus/rice bran extract/soybean extract ferment filtrate, 0.5-1.0% of Streptococcus thermophilus ferment, 0.1-0.2% of collargol, and 65.3-79.4% of deionized water, wherein the essence is put in an airtight container and is injected with hydrogen. The present invention can achieve an effect of repairing the skin, and the combination of active substances with the hydrogen injected has a prominent effect on reducing the amount of allergic erythema and alleviating the recurrent allergic redness and rashes.

The present invention relates to a multi-postbiotics-compounded rejuvenating essence, which includes the following components in percentage by weight: 8.0-13.0% of butanediol, 2.0-3.0% of triglyceride octoate/caprate/succinate, 2.0-3.0% of polyglutamate sodium, 0.5-1.0% of extract of Japanese Ardisia herb stems, 0.5-1.0% of yeast/rice ferment filtrate, 0.5-1.0% of fission yeast mycelium ferment filtrate, 0.5-1.0% of lactobacillus/mung bean extract/sodium glutamate ferment filtrate, 0.5-1.0% of lactobacillus ferment, 0.5-1.0% of bacillus/rice bran extract/soybean extract ferment filtrate, 0.5-1.0% of Streptococcus thermophilus ferment, 0.1-0.2% of collargol, and 65.3-79.4% of deionized water, wherein the essence is put in an airtight container and is injected with hydrogen. The present invention can achieve an effect of repairing the skin, and the combination of active substances with the hydrogen injected has a prominent effect on reducing the amount of allergic erythema and alleviating the recurrent allergic redness and rashes.

Methods are provided for treating and diagnosing diseases and disorders associated with retinal degeneration, such as retinitis pigmentosa. Dietary supplementation with specific metabolites and vitamins can prolong vision and provide a neuroprotective effect. In particular, dietary supplementation with α-ketoglutarate, or a derivative thereof, significantly prolongs photoreceptor cell survival and visual function. In addition, dietary supplementation with B vitamins and a ketogenic diet also improves photoreceptor cell survival and delays disease progression in some cases. Additionally, compositions, methods, and kits are provided for diagnosing a subject with retinitis pigmentosa based on expression levels of vitreous biomarkers.

Methods are provided for treating and diagnosing diseases and disorders associated with retinal degeneration, such as retinitis pigmentosa. Dietary supplementation with specific metabolites and vitamins can prolong vision and provide a neuroprotective effect. In particular, dietary supplementation with α-ketoglutarate, or a derivative thereof, significantly prolongs photoreceptor cell survival and visual function. In addition, dietary supplementation with B vitamins and a ketogenic diet also improves photoreceptor cell survival and delays disease progression in some cases. Additionally, compositions, methods, and kits are provided for diagnosing a subject with retinitis pigmentosa based on expression levels of vitreous biomarkers.

Methods of reactivating latent human immunodeficiency virus (HIV) in one or more cells of a patient infected with HIV are provided. Methods of treating HIV infection and acquired immune deficiency syndrome (HIV/AIDS) in a patient are also provided. The methods can include administering a crotonylation-inducing agent to the patient. The methods can also include administering a crotonylation-inducing agent and one or more additional latency reversal agents (LRAs) to the patient. Pharmaceutical compositions including a crotonylation-inducing agent or pharmaceutical compositions including a crotonylation-inducing agent and one or more additional LRAs are also provided.

Methods of reactivating latent human immunodeficiency virus (HIV) in one or more cells of a patient infected with HIV are provided. Methods of treating HIV infection and acquired immune deficiency syndrome (HIV/AIDS) in a patient are also provided. The methods can include administering a crotonylation-inducing agent to the patient. The methods can also include administering a crotonylation-inducing agent and one or more additional latency reversal agents (LRAs) to the patient. Pharmaceutical compositions including a crotonylation-inducing agent or pharmaceutical compositions including a crotonylation-inducing agent and one or more additional LRAs are also provided.

Aspects of the present disclosure include fatty acid β-hydroxyester compounds (e.g., fatty acid esters of β-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid β-hydroxyester compounds and/or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.

Aspects of the present disclosure include fatty acid β-hydroxyester compounds (e.g., fatty acid esters of β-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid β-hydroxyester compounds and/or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.

An affordable, palatable, maintainable and clinically-useful UC diet, characterized by a low content of sulfur, heme animal-based protein, taurine, animal-saturated fat.